Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Valneva SE
  6. News
  7. Summary
    VLA   FR0004056851

VALNEVA SE

(VLA)
  Report
Real-time Euronext Paris  -  11:37 2022-08-18 am EDT
9.906 EUR   -0.04%
01:41pValneva Initiates Rolling Submission of US FDA Biologics License Application for Chikungunya Vaccine
MT
12:01pValneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
GL
12:00pValneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Valneva Reiterates Timelines for Lyme Disease, Chikungunya Vaccine Candidates

06/24/2022 | 01:38am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
PFIZER, INC. -1.63% 48.46 Delayed Quote.-16.56%
VALNEVA SE -0.04% 9.906 Real-time Quote.-59.55%
All news about VALNEVA SE
01:41pValneva Initiates Rolling Submission of US FDA Biologics License Application for Chikun..
MT
12:01pValneva Initiates Rolling Submission of FDA Biologics License Application for its Singl..
GL
12:00pValneva Initiates Rolling Submission of FDA Biologics License Application for its Singl..
AQ
10:28aValneva's COVID-19 Vaccine Recommended for Use by World Health Organization
MT
09:45aWHO recommends Valneva's COVID vaccine
RE
09:20aWHO recommends Valneva's COVID vaccine
RE
05:38aValneva Says Pentagon Didn't Exercise 2nd Option Year of Supply Contract for Japanese E..
MT
03:14aVALNEVA : U.S. Dept of Defense ends Ixiaro vaccine supply deal
RE
01:22aValneva Says US Defense Department Waived Second-year Supply Option For Japanese Enceph..
MT
01:10aVALNEVA : U.S. Dept of Defense ends Ixiaro vaccine supply deal
RE
More news
Analyst Recommendations on VALNEVA SE
More recommendations
Financials
Sales 2022 337 M 341 M 341 M
Net income 2022 9,30 M 9,43 M 9,43 M
Net cash 2022 290 M 294 M 294 M
P/E ratio 2022 124x
Yield 2022 -
Capitalization 1 162 M 1 177 M 1 177 M
EV / Sales 2022 2,59x
EV / Sales 2023 3,42x
Nbr of Employees 700
Free-Float 68,2%
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 9,91 €
Average target price 15,92 €
Spread / Average Target 60,6%
EPS Revisions
Managers and Directors
Thomas Lingelbach President & Chief Executive Officer
Franck Charles Marie Grimaud Director General & Chief Business Officer
Peter Buhler Chief Financial Officer
Frédéric Grimaud Chairman-Supervisory Board
Michael Möhlen Vice President-Technical Development
Sector and Competitors
1st jan.Capi. (M$)
VALNEVA SE-59.55%1 181
MODERNA, INC.-37.79%61 810
IQVIA HOLDINGS INC.-14.72%44 878
LONZA GROUP AG-26.39%43 629
SEAGEN INC.10.47%31 500
ALNYLAM PHARMACEUTICALS, INC.31.58%26 782